ERBB2 and breast carcinoma: To sum up, T-DM1 is a relatively safe and effective agent in the treatment of advanced or metastatic HER2-positive breast cancer, even among patients with asymptomatic or treated brain metastases and trastuzumab resistance14, 15, 16, 25, 27, 34, 35, 36, 37.